BCT-100 is under clinical development by Bio-Cancer Treatment International and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect BCT-100’s likelihood of approval (LoA) and phase transition for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) took place on 05 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 05 Sep 2022 increased BCT-100’s Phase Transition Success Rate (PTSR) for High-Grade Glioma, increased LoA and PTSR for Neuroblastoma, increased LoA and PTSR for Refractory Acute Myeloid Leukemia, increased LoA and PTSR for Relapsed Acute Myeloid Leukemia, and increased PTSR for Sarcomas.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their BCT-100 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

BCT-100 overview

BCT-100 (PEG-BCT-100) is under development for the treatment of hepatocellular carcinoma, melanoma, hormone refractory prostate cancer, relapsed/refractory acute lymphoblastic leukemia, relapsed/refractory acute myeloid leukemia (AML), neuroblastoma, sarcoma, and high-grade gliomas. The drug candidate is administered through the intravenous route. It is a pegylated recombinant human arginase in phosphate saline buffer. It acts by targeting arginine. The drug candidate is developed using chemical synthetic technology. It was also under development for the treatment of relapsed/refractory lymphoma, renal cell carcinoma, lung adenocarcinoma, and astrocytoma.

Bio-Cancer Treatment International overview

Bio-Cancer Treatment International (BCT) is a clinical-stage biopharmaceutical company that offers research and development of biologics. The company’s products comprise BCT-100 and BCT-200. Its BCT-100 provides pegylated recombinant human arginase being developed for arginine depletion therapy in arginine auxotrophic cancers. BCT’s BCT-200 is a modification of BCT-100 with alterations to the amino acid sequence being developed for arginine depletion therapy in autoimmune disorders and other potential indications. The company develops innovative biologics for the treatment of human malignancies and auto-immune disorders. It has its presence in Shanghai and Hong Kong. BCT is headquartered in Hong Kong.

Quick View BCT-100 LOA Data

Report Segments
  • Innovator
Drug Name
  • BCT-100
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.